KMT2A and breast cancer: However, published reports suggest that the MLL enzyme MLL4/KMT2D is an AKT substrate, and its enzymatic activity is associated with resistance to the PI3K inhibitor alpelisib in HR+ breast cancer via epigenome-driven upregulation of ER signaling (7).